Fintel reports that on December 20, 2024, Rodman & Renshaw initiated coverage of Atara Biotherapeutics (NasdaqGS:ATRA) with a Buy recommendation.
Analyst Price Forecast Suggests 51.51% Upside
As of December 3, 2024, the average one-year price target for Atara Biotherapeutics is $15.04/share. The forecasts range from a low of $10.10 to a high of $22.05. The average price target represents an increase of 51.51% from its latest reported closing price of $9.93 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Atara Biotherapeutics is 82MM, a decrease of 18.51%. The projected annual non-GAAP EPS is -1.84.
What is the Fund Sentiment?
There are 65 funds or institutions reporting positions in Atara Biotherapeutics. This is an decrease of 32 owner(s) or 32.99% in the last quarter. Average portfolio weight of all funds dedicated to ATRA is 0.01%, an increase of 26.88%. Total shares owned by institutions decreased in the last three months by 9.55% to 2,460K shares. 
The put/call ratio of ATRA is 1.29, indicating a bearish outlook.
What are Other Shareholders Doing?
EcoR1 Capital holds 469K shares representing 8.14% ownership of the company. In its prior filing, the firm reported owning 407K shares , representing an increase of 13.28%. The firm increased its portfolio allocation in ATRA by 23.40% over the last quarter.
Redmile Group holds 452K shares representing 7.85% ownership of the company. No change in the last quarter.
Citadel Advisors holds 260K shares representing 4.52% ownership of the company. No change in the last quarter.
Bank Of America holds 204K shares representing 3.54% ownership of the company. In its prior filing, the firm reported owning 186K shares , representing an increase of 8.65%. The firm decreased its portfolio allocation in ATRA by 1.63% over the last quarter.
Millennium Management holds 176K shares representing 3.06% ownership of the company. In its prior filing, the firm reported owning 117K shares , representing an increase of 33.73%. The firm increased its portfolio allocation in ATRA by 47.79% over the last quarter.
Atara Biotherapeutics Background Information
(This description is provided by the company.)
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
